Perspectives
Where the frontier is moving, and what to do about it.
Short, sourced reads from Xcubed on innovation in China, the US and India, and how leaders turn access into decisions.
Health and pharma
Your next drug may be licensed from China
A third of global pharma licensing value now starts in Chinese labs. If your pipeline strategy still treats China as a manufacturing base, you are reading last decade's map.
5 min read MethodA week on the ground beats a stack of reports
The innovation frontier is now spread across three continents. You cannot brief your way to conviction about a place you have never stood in. Here is why we sell the room, not the report.
4 min readBy the numbers
$285.9bn
US private AI investment in 2025, about 83% of the global total.
Stanford HAI AI Index, 2026~$136bn
Roughly a third of global pharma licensing value now comes from China.
PharmCube / Caixin, 20251,700+
Global capability centres in India, employing about 1.9m people.
NASSCOM / Zinnov, 2025